THE BRIGHAM & WOMENS HOSPITAL INC.;THE BRIGHAM & WOMEN'S HOSPITAL INC.
发明人:
SERHAN, Charles N.,DALLI, Jesmond
申请号：
USUS2014/037969
公开号：
WO2014/193652A3
申请日:
2014.05.14
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The invention describes novel mono-hydroxy, di-hydroxy and tri-hydroxy docosapentaenoic acid (DPA) analogues, their preparation, isolation, identification, purification and uses thereof. Resolution of inflammation is now held to be an active process where autacoids promote homeostasis. Using functional-metabololipidbmics and in vivo systems, endogenous n-3 docosapentaenoic (DP A) acid is converted during inflammation-resolution in mice and by human leukocytes to novel n-3 products congenerous to D-series resolvins (Rv), protectins (PD) and maresins (MaR), termed specialized pro-resolving mediators (SPM). The new n-3 DPA structures include 7,8,17-trihydroxy-9,11,13,15E, 19Zdocosapentaenoic acid (RvD1n_3 DPA), 7, 14-dihydroxy-8, 10, 12, 16Z, 19Z-docosapentaenoic acid (MaR1n_3 DPA) and related bioactive products.L'invention concerne de nouveaux analogues de l'acide docosapentaénoïque (DPA) mono-hydroxy, di-hydroxy et tri-hydroxy, leur préparation, leur isolement, leur identification, leur purification et leurs utilisations.
